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Plerixafor and G-CSF combination mobilizes
hematopoietic stem and progenitors cells with a dis-
tinct transcriptional profile and a reduced in vivo
homing capacity compared to plerixafor alone
For decades, bone marrow (BM) has been the preferred
source of hematopoietic stem and progenitor cells
(HSPCs) for transplants following myeloablative condi-
tioning. At present, mobilized peripheral blood stem cells
are commonly used for transplantation, particularly in
the autologous setting.1
Hematopoietic stem cells (HSCs) are maintained in
their niche by binding to adhesion molecules and diverse
strategies are used to promote their egress from BM to
peripheral blood (PB).2 Granulocyte-colony stimulating
factor (G-CSF) represents the gold standard agent to
mobilize HSPCs for transplantation. Nevertheless, other
compounds have recently been tested.3
One of the most successful mobilizing agents is plerix-
afor,4 a bicyclam molecule that selectively and reversibly
antagonizes the binding of stromal cell derived factor-1
(SDF-1) on the surface of BM stromal cells, to chemokine
CXC-receptor-4 (CXCR4) on HSPCs, with their subse-
quent mobilization in the blood. Clinical trials demon-
strated that plerixafor alone safely and rapidly mobilizes
HSCs in healthy donors, β-thalassemia patients and
patients affected by malignancies.3,5,6 
Characterization studies of non-human primates and
human samples of plerixafor-mobilized cells in compari-
son to cells mobilized by G-CSF alone or in combination
with plerixafor showed a different expression profile, cell
composition and engrafting potential in xenotransplant
models.7-11 
However, these studies did not solve whether plerix-
afor, G-CSF, or their combination mobilizes different
primitive HSC populations. 
In order to define the content of HSPCs mobilized by
plerixafor, CD34+ cells were isolated from leukapheresis
(Plx PB), steady-state BM and BM following plerixafor
administration (Plx BM) of thalassemic patients enrolled
in a phase II trial of mobilization. 
We performed a detailed immunophenotype analysis
of primitive HSPCs by using the “gold standard” cell sur-
face markers.12
The analysis revealed an increased frequency of long-
term HSCs (LT-HSCs) and a decrease in intermediate
HSCs (INT-HSCs) in Plx PB versus BM. Moreover, multi-
potent progenitor (MPP) frequency was lower in Plx PB
samples as compared to BM and Plx BM, indicating that
they are not predominantly mobilized by plerixafor
(Figure 1A,B).
To identify the molecular mechanisms underlying the
higher quality of plerixafor-mobilized HSPCs, gene
expression profiling was performed on CD34+ cell sam-
ples isolated from the same individuals (n=3). Principal
component analysis (PCA) revealed a segregation of Plx
PB, BM and Plx BM in three discrete clusters on the basis
of the cell source (Figure 1C). Plx BM samples were posi-
tioned between Plx PB and BM, suggesting that the tran-
scriptional profile begins to change by plerixafor admin-
istration and progressed in HSPCs collected by leuka-
pheresis. 
Comparing Plx PB to BM samples, we identified 829
differentially expressed  probe sets (Online Supplementary
Table S1). 37% of the probe sets was significantly upreg-
ulated in plerixafor-mobilized CD34+ cells, whereas the
expression of 523 probe sets was greater in BM (FDR <
0.05). Cluster analysis showed that Plx BM clustered
with BM samples indicating that these cells share many
similarities (Figure 1D). Most of the probe sets upregulat-
ed in Plx PB were enriched in cellular and metabolic
processes, while most of the downregulated probe sets
were involved in cell cycle processes13 (Online
Supplementary Figure S1A-D), including MIK67, cyclins,
CDC6, CHEK1, BRCA1, BRCA2, kinases and transcrip-
tion factors related to cell proliferation (Online
Supplementary Figure S2A and Online Supplementary Table
S2). Another characteristic of Plx PB is the underexpres-
sion of DNA repair genes associated to the S-phase of cell
cycle, such as RAD51, FEN1 and TOP2A (Online
Supplementary Table S2), suggesting that Plx PB is
enriched in HSCs, characterized by a slow division rate
since quiescent. By using this gene list (PROGENITORS_
PROGRAM), gene set enrichment analysis (GSEA)
revealed that BM samples were enriched in markers of
proliferation (P<0.01, Online Supplementary Figure S2B).
Performing a meta-analysis on gene expression data
from human purified hematopoietic subpopulations, we
identified  174 genes upregulated in HSCs and multipo-
tent progenitors (MPPs) (METAHSC_SIGNATURE)
(Online Supplementary Figure S2). GSEA analysis revealed
that Plx PB samples were enriched in METAHSC_SIGNA-
TURE (P<0.01, Figure 1D), with a gene expression profile
positively correlated with primitive gene sets (Figure 1E). 
We selected genes (Online Supplementary Table S3) for
transcription factors playing a key role in HSC regulation
(HSC expression program):13 MECOM, MEIS1, HOXB3,
ZKSCAN1 and HLF.14 These genes were found signifi-
cantly upregulated in Plx PB compared to BM and Plx BM
cells (Figure 1F). This program is already active in cells
primed by plerixafor (Plx BM), indicating an early change
in subpopulation composition (Figure 1F). This finding
might be due to a direct transcriptional activation by the
drug on resident cells, or to the contribution of circulating
plerixafor CD34+ cells in the BM harvest, although these
hypotheses are difficult to test. 
In order to proceed to comparative studies including
other clinically relevant HSC sources, available mostly
from healthy donors (HD), we performed immunophe-
notype and gene expression profile analysis of BM-
derived CD34+ cells from thalassemic patients (THAL)
and HD. No differences were observed in LT-HSC fre-
quencies (Online Supplementary Figure S4) and in gene
expression profile (Online Supplementary Table S4), thus
excluding a disease-related contribution to specific prop-
erties, at least in the CD34+ bulk population. These
results were confirmed by analysis on pediatric samples
(manuscript in preparation). 
Extending immunophenotype analysis to other stem
cells sources (Online Supplementary Figure S5A), a higher
percentage of LT-HSCs was observed in Plx PB cells com-
pared to G-CSF-mobilized cells (G-CSF PB), which are
indeed preferentially enriched in MPPs and INT-HSCs
(Figure 2A,B). Interestingly, the combined use of G-CSF
and plerixafor (G+Plx PB) mobilizes a LT-HSCs popula-
tion similar to that found in G-CSF PB, but with a lower
frequency of INT-HSCs and MPPs (Figure 2A,B). 
Since SDF1-CXCR4 signaling is essential to maintain
the HSC pool, and plerixafor is able to interfere with this
axis, we reasoned that the cells might be enriched with
functionally primitive HSCs. Therefore, we performed a
limiting dilution assay in NOD/ShiLtSz-scid/IL2Rγnull
(NSG) mice to calculate the frequency of primitive severe
combined immunodeficiency (SCID) repopulating cells
(SRCs).
Sub-lethally irradiated mice were transplanted with
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escalating doses of CD34+ cells from Plx PB, G-CSF PB,
G+Plx PB and BM. Limiting dilution assay showed that
the SRC frequencies of Plx PB, G-CSF PB, G+Plx PB and
BM were 1/47875, 1/141203, 1/201803 and 1/56020
CD34+ cells, respectively (Figure 2C, Online Supplementary
Table S5) with statistically significant differences between
Plx PB versus G+Plx PB  and Plx PB versus G-CSF PB
(Figure 2C, Online Supplementary Table S6). These data are
in accordance with previous results.7,10
Since the signaling provided by the interaction of SDF1
with CXCR4 also plays an essential role in the migration
of transplanted cells toward the BM niche, likewise in the
xenotransplantation model,15 we evaluated the CXCR4
expression and the in vivo homing capacity of BM, G-CSF
PB, Plx PB and G+Plx PB. Flow cytometry results revealed
that CXCR4 expression was lower in G-CSF PB CD34+
cells (Online Supplementary Figure S5B), whereas the
analysis restricted to the primitive compartment of
CD34+CD38-/low cells, showed a lower percentage of
CXCR4+ cells in the G+Plx PB source (Figure 2D). These
data suggest that the reduced reconstitution activity of
both G-CSF- and G+Plx-mobilized cells observed in SRCs
assay could be the result of a lower frequency of CXCR4+
primitive cells. 
To address this issue, CD34+CD38-/low cells from CD34+
samples were examined for their in vivo homing potential
by non-invasive bioluminescent imaging (BLI). After
24hrs, mice injected with Plx PB cells exhibited a higher
signal than those with cells from BM, G-CSF PB and
G+Plx PB (Figure 2E), despite comparable transduction
efficiencies (Online Supplementary Figure S5C). The most
relevant differences were between Plx PB versus G+ Plx
PB (P<0.001) and Plx PB versus G-CSF PB (P<0.05) groups
(Figure 2F). Thus, we could ascribe the reduced number
of SRCs mobilized by G-CSF and G+Plx to a lower
migrating and long-term repopulating capacity compared
to plerixafor-mobilized cells. 
When the transcriptional relationships among different
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Figure 1. Cell surface marker and gene
expression analysis of primitive HSPCs in
paired sources derived from thalassemic
patients. A. Distribution of LT-HSCs, INT-
HSCs and MPPs in different sources
derived from thalassemic patients:  BM
(n=2), Plx BM (n=3) and Plx PB (n=3). The
expression of CD38, CD90, CD45RA and
CD49f cell surface markers is considered
the “gold standard” for predicting primitive
HSCs.12 Using these markers three main
subpopulations of CD34+ cells were identi-
fied: HSCs (CD34+ CD38-/low CD90+/-
CD45RA– CD49f+); LT-HSCs (CD34+ CD38-/low
CD90+ CD45RA– CD49f+); INT-HSC (CD34+
CD38-/low CD90– CD45RA- CD49f+); MPPs
(CD34+ CD38-/low CD90- CD45RA– CD49f–).
The indicated subsets are reported as rela-
tive fractions of the more primitive
hematopoietic populations (gated on
CD34+ CD38-/low CD90+/- CD45RA– cells).
Data are represented as mean±SEM. B.
Population distance analysis of microarray
data presented in three principal compo-
nents (PCs1-3). Each point represents a
single array. Stem cell sources are color-
coded.  C. Hierarchical cluster analysis to
assess relative distance of the transcrip-
tome of each stem cell source. The
branched tree is based on differentially
expressed genes in plerixafor-mobilized
CD34+ cells versus BM (FDR<0.05). In this
image, the normalized expression levels of
genes are presented according to a colored
gradient from the highest (red) to lowest
(blue, see colored scale). D. GSEA plot
enrichment of METAHSC_SIGNATURE in Plx
PB (n=3) vs. BM (n=3) expression profile
(P<0.01).  E. Our data were compared with
previously generated gene sets METAH-
SC_SIGNATURE (Online Supplementary
Figure S3), derived from bone marrow stem
and progenitor population. Plx PB gene
expression positively correlates with primi-
tive gene sets.  F. Heat maps of selected
genes involved in HSC regulation are more
highly expressed in Plx PB than in other
samples. PCA: principal component analy-
sis; BM: bone marrow; PB: peripheral
blood; HSC: hematopoietic stem cell; LT-
HSC: long-term HSC; INT-HSC: intermediate
HSC; MPP: multipotent progenitor.
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mobilized PB CD34+ samples (Plx PB, G-CSF PB and
G+Plx PB) were analyzed, we observed that METAH-
SC_SIGNATURE and HSC expression program are pref-
erentially expressed in Plx PB samples compared to the
others (Figure 3A,B), whereas the PROGENITOR_PRO-
GRAM is particularly active in G+Plx PB cells (Figure 3C).
The differences in gene expression profile reflect the cell
composition, both in terms of primitive immature (Figure
2) and more mature progenitors (Figure 3D). 
In summary, we show that HSCs from different
sources are endowed with specific properties. Plerixafor-
mobilized cells possess the highest ability to home to
hematopoietic niches and engraft in immunodeficient
mice. The higher content of CXCR4+ and CD49f+ cells
correlates with this feature, whereas the reduced number
of SRCs and homing capacity of G-CSF- and G+Plx-mobi-
lized cells could be ascribed to lower expression of
CXCR4 due to a direct effect of G-CSF.7,11 Global gene
expression profiling highlights the superior in vivo recon-
stitution activity of plerixafor-mobilized cells. We
hypothesized that the “stemness” signature of cells dis-
lodged from their niche by plerixafor is attenuated by the
combined use with G-CSF, which emphasizes the gene
expression profile induced by G-CSF treatment. Since the
number of analyzed samples is limited, in addition, fur-
ther studies on purified subpopulations will define if the
combined use of the two drugs affects the self-renewal of
LT-HSCs. These findings suggest the use of more primi-
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Figure 2. Hierarchy of HSC sources.
A. Analysis of the frequencies of prim-
itive hematopoietic stem cells LT-HSC,
INT-HSC and MPP (B) in BM (n=9), G-
CSF (n=3), Plx  (n=3) and G+Plx (n=2)
CD34+ cells. Data are represented as
mean±SEM. C. Stem cell frequency: a
single-hit Poisson model was used to
calculate the SRC frequency at limit-
ing dilution for cells derived from Plx
PB, G-CSF PB, G+Plx PB and from BM.
Mice (n=123) were considered
engrafted if the frequency of human
cells was ≥1%CD45+. ELDA software
was used to calculate the SRC fre-
quency. The calculated SRC frequency
is 1/47875 in plerixafor-mobilized
CD34+ cells, 1 SRC in 141203 
G-CSF-mobilized CD34+ cells and 1
SRC in 1/201803 G+Plx PB. The fre-
quency in BM is 1 SRC in 56020
CD34+ cells.  D. Percentage of CXCR4+
in CD34+ CD38-/low was analyzed in all
samples.  It was statistically signifi-
cantly higher in plerixafor-mobilized
cells compared to all samples
(*P<0.05). Data are represented as
mean±SEM. E. Sorted CD34+ CD38-/low
cells were transduced with a LV-
PGK/Luc and transplanted in NSG
mice. Four different cohorts of mice
(n=3/each group) were generated by
transplantation of BM (CD34+ cells
from a pool of 5 donors), G-CSF PB
(pool of 3 donors), Plx PB (pool of 3
donors) and G+Plx PB (pool of 2
donors). 24hrs after injection into the
mouse circulation, a BLI signal ema-
nating from the area corresponding to
the femurs was detected. 
F. Histogram represents total Flux
[p/s] emanating from the area corre-
sponding to  both femurs. Mice that
received the CD34+CD38-/low cells iso-
lated from Plx PB exhibited higher sig-
nals than those that received the
CD34+CD38-/low cells isolated from
other sources. (***P<0.001;
*P<0.05). Data are represented as
mean±SEM. BM: bone marrow; PB:
peripheral blood; HSC: hematopoietic
stem cell; LT-HSC; long-term HSC; INT-
HSC: intermediate HSC; MPP: multi-
potent progenitor. 
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tive HSCs when target cell numbers for transplantation is
limited, or when disease related characteristics dictate
caution in the choice of G-CSF as a mobilizing agent.
Regarding the population mobilized by both G-CSF and
plerixafor, the reduction of SRCs is counterbalanced by
the superior harvest of mobilized cells, since the single
addition of plerixafor synergizes with multiple doses of
G-CSF to mobilize greater numbers of CD34+/kg than
that obtained by a single agent.5
Among the different hypotheses on the effect of com-
bined mobilizing agents, on the basis of our results, we
hypothesized that plerixafor mobilizes cells previously
partially disengaged from the BM niche and/or expanded
by G-CSF. Further studies will contribute to dissecting the
molecular basis underlying the direct and indirect actions
of single and combined treatment on the HSC compart-
ment in humans.
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Figure 3. 'Stemness' signature in
mobilized CD34+ cell sources. A.
Hierarchical cluster analysis to assess
relative distance of the transcriptome
of each stem cell source. Data from
mobilized stem cell sources were
compared with previously generated
gene sets derived from bone marrow
stem and progenitor population
(Online Supplemenary Figure S3). Plx
PB gene expression was positively
correlated with primitive gene sets. B.
Heat maps of selected genes involved
in HSC regulation are more highly
expressed in Plx PB than in other
stem cell sources. C. Heat map of reg-
ulators of cell cycle and DNA repair,
showing an enrichment in the progen-
itor associated program in G+Plx PB
expression profile. In these images,
the normalized expression levels of
genes are presented according to a
colored gradient from the highest
(red) to lowest (blue, see colored
scale). D. Immunophenotypic analysis
of progenitor composition in G-CSF
PB, Plx PB and G+Plx PB sources. G-
CSF PB (n=2); Plx PB (n=3); G+Plx PB
(n=2): CMP, common myeloid progen-
itor (CD34+ CD38+ CD45RA– CD135+
CD10- CD7-), GMP, granulocyte-
macrophage progenitor (CD34+
CD38+ CD45RA+ CD135+ CD10–
CD7–), MEP, megakaryocyte-erythro-
cyte progenitor (CD34+ CD38+
CD45RA– CD135– CD10– CD7–), and
CLP, common lymphoid progenitor
(CD34+ CD38+ CD45RA+ CD10+ CD7–).
The CLP, CMP, GMP and MEP subsets
are reported as percentages of CD34+
cells, according to the expression of
CD34, CD38, CD45RA, CD135, CD10
and CD7 surface markers.
Statistically significant differences
were observed by comparing the
three mobilized sources with the high-
er CMP and the lower MEP content in
G+Plx PB samples, as compared to G-
CSF PB and Plx PB, respectively
(P<0.05). Data are represented as
mean±SEM. PB: peripheral blood.
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